US earmarks up to $680M for Chimerix’s smallpox drug Tembexa, clearing way for Emergent buyout

US earmarks up to $680M for Chimerix’s smallpox drug Tembexa, clearing way for Emergent buyout

Source: 
Fierce Pharma
snippet: 

During the latest monkeypox outbreak, doctors in the U.S. have been treating patients with Siga Technologies’ smallpox drug Tpoxx. Now, the U.S. government may have a second potential antiviral option at its disposal.